Coya Therapeutics (COYA) announced the issuance of a U.S. patent relevant to its investigational ready-to-use liquid formulation of IL-2. In particular, the U.S. Patent and Trademark Office, USPTO, has granted patent number US 12,312,389 B2, which covers methods of producing highly stable liquid formulations of IL-2. Through an existing agreement, Coya has the exclusive in-vivo rights to this patent and other related intellectual property spanning multiple indications both as monotherapy and combination therapies.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COYA:
- Coya Therapeutics: Promising Developments and Strategic Partnerships Drive Buy Rating
- Coya Therapeutics Reports Q1 2025 Financial Results
- Coya Therapeutics reports Q1 EPS (44c), consensus (12c)
- Promising Outlook for Coya Therapeutics: Buy Rating Justified by Innovative Treatments and Pipeline Potential
- Coya Therapeutics reports interim results from IL-2, CTLA4-Ig combination study